Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
Phase III Clinical Trial
A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)